Answers are grounded in this paper and cite their sources.
Inhibition of FASN reduces CD4+ T cell hyperactivation in Sjögren’s syndrome, implying a potential treatment target.
FASN drives CD4⁺ T cell hyperactivation and metabolic reprogramming in SS. Its inhibition shifts cell metabolism from glycolysis to OXPHOS, reducing inflammation and ameliorating disease in preclinical models. These results identify FASN as a potential therapeutic target for SS.
No takes yet. Share an insight, caveat, or question.
Ye et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: